Cano Health (CANO) Stock Forecast, Price Target & Predictions
CANO Stock Forecast
Cano Health stock forecast is as follows: an average price target of $6.42 (represents a 1505.00% upside from CANO’s last price of $0.40) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
CANO Price Target
CANO Analyst Ratings
Cano Health Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Jan 06, 2023 | - | UBS | $1.25 | $1.10 | 13.64% | 212.50% |
Nov 16, 2022 | - | Citigroup | $5.00 | $2.04 | 144.79% | 1150.00% |
May 10, 2022 | Jason Cassorla | Citigroup | $8.00 | $4.13 | 93.94% | 1900.00% |
Apr 20, 2022 | - | UBS | $15.00 | $5.16 | 190.70% | 3650.00% |
Mar 18, 2022 | Gary Taylor | Cowen & Co. | $13.00 | $6.99 | 85.98% | 3150.00% |
Jan 14, 2022 | Jason Cassorla | Citigroup | $12.00 | $6.51 | 84.33% | 2900.00% |
Cano Health Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | - |
Avg Price Target | - | - | - |
Last Closing Price | $0.40 | $0.40 | $0.40 |
Upside/Downside | -100.00% | -100.00% | -100.00% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Jan 06, 2023 | UBS | - | Neutral | Downgrade |
Nov 16, 2022 | Citigroup | Buy | Buy | Hold |
Jun 24, 2022 | Raymond James | - | Outperform | Initialise |
May 10, 2022 | Citigroup | Buy | Buy | Hold |
Cano Health Financial Forecast
Cano Health Revenue Forecast
Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Mar 22 | Sep 21 | Jun 21 | |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | $788.07M | $766.75M | $866.91M | $704.34M | $526.80M | $393.16M |
Avg Forecast | $1.73B | $1.53B | $1.34B | $710.55M | $759.84M | $828.43M | $826.34M | $666.03M | $435.67M | $306.85M |
High Forecast | $1.76B | $1.57B | $1.37B | $711.00M | $772.00M | $845.87M | $843.74M | $680.06M | $444.84M | $313.31M |
Low Forecast | $1.71B | $1.52B | $1.33B | $710.10M | $742.40M | $820.37M | $818.30M | $659.55M | $431.43M | $303.86M |
# Analysts | - | - | 1 | 2 | 3 | 1 | 1 | 1 | 1 | 1 |
Surprise % | - | - | - | - | 1.04% | 0.93% | 1.05% | 1.06% | 1.21% | 1.28% |
Cano Health EBITDA Forecast
Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Mar 22 | Sep 21 | Jun 21 | |
---|---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | 1 | 2 | 3 | 1 | 1 | 1 | 1 | 1 |
EBITDA | - | - | - | - | $-65.86M | $-142.09M | $-5.88M | $11.29M | $-33.60M | $25.12M |
Avg Forecast | $38.65M | $34.35M | $30.06M | $15.92M | $17.02M | $18.56M | $18.51M | $27.79M | $-36.96M | $6.87M |
High Forecast | $39.46M | $35.08M | $30.69M | $15.93M | $17.29M | $18.95M | $18.90M | $33.35M | $-29.57M | $7.02M |
Low Forecast | $38.27M | $34.02M | $29.77M | $15.91M | $16.63M | $18.38M | $18.33M | $22.23M | $-44.36M | $6.81M |
Surprise % | - | - | - | - | -3.87% | -7.66% | -0.32% | 0.41% | 0.91% | 3.65% |
Cano Health Net Income Forecast
Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Mar 22 | Sep 21 | Jun 21 | |
---|---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | 1 | 2 | 3 | 1 | 1 | 1 | 1 | 1 |
Net Income | - | - | - | - | $-260.49M | $-140.75M | $-28.15M | $-85.00K | $-67.13M | $9.48M |
Avg Forecast | $813.63M | $708.69M | $832.13M | $-100.29M | $-121.41M | $-47.51M | $-73.90M | $1.22M | $-73.84M | $-38.71M |
High Forecast | $25.13B | $21.89B | $25.70B | $-5.81B | $-7.39B | $-1.47B | $-2.28B | $1.46M | $-59.07M | $-1.20B |
Low Forecast | $43.42B | $37.82B | $44.40B | $-10.03B | $-12.14B | $-2.53B | $-3.94B | $975.52K | $-88.61M | $-2.07B |
Surprise % | - | - | - | - | 2.15% | 2.96% | 0.38% | -0.07% | 0.91% | -0.24% |
Cano Health SG&A Forecast
Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Mar 22 | Sep 21 | Jun 21 | |
---|---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | 1 | 2 | 3 | 1 | 1 | 1 | 1 | 1 |
SG&A | - | - | - | - | $80.82M | $99.42M | $96.47M | $96.59M | $75.93M | $46.57M |
Avg Forecast | $258.60M | $229.87M | $201.13M | $106.51M | $113.90M | $124.18M | $123.87M | $178.45M | $83.52M | $46.00M |
High Forecast | $264.05M | $234.71M | $205.37M | $106.58M | $115.72M | $126.79M | $126.48M | $214.14M | $100.22M | $46.96M |
Low Forecast | $256.08M | $227.63M | $199.18M | $106.44M | $111.28M | $122.97M | $122.66M | $142.76M | $66.81M | $45.55M |
Surprise % | - | - | - | - | 0.71% | 0.80% | 0.78% | 0.54% | 0.91% | 1.01% |
Cano Health EPS Forecast
Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Mar 22 | Sep 21 | Jun 21 | |
---|---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | 1 | 2 | 3 | 1 | 1 | 1 | 1 | 1 |
EPS | - | - | - | - | $-91.87 | $-0.00 | $-0.12 | $-0.00 | $-0.09 | $0.06 |
Avg Forecast | $1.54 | $1.34 | $1.58 | $-0.19 | $-0.23 | $-0.09 | $-0.14 | $-0.10 | $-0.00 | $-0.07 |
High Forecast | $47.61 | $41.47 | $48.69 | $-11.00 | $-14.00 | $-2.78 | $-4.32 | $-3.09 | $-0.05 | $-2.27 |
Low Forecast | $82.25 | $71.64 | $84.12 | $-19.00 | $-23.00 | $-4.80 | $-7.47 | $-5.34 | $-0.08 | $-3.91 |
Surprise % | - | - | - | - | 399.43% | 0.01% | 0.86% | 0.00% | 59.60% | -0.82% |
Cano Health Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
TOI | Oncology Institute | $0.28 | $8.00 | 2757.14% | Buy |
CANO | Cano Health | $2.30 | $6.42 | 179.13% | Buy |
ACHC | Acadia Healthcare Company | $42.33 | $82.33 | 94.50% | Buy |
AGL | agilon health | $2.67 | $4.40 | 64.79% | Buy |
EHAB | Enhabit | $7.63 | $10.25 | 34.34% | Hold |
BKD | Brookdale Senior Living | $6.24 | $7.50 | 20.19% | Buy |
AMEH | Astrana Health | $40.82 | $48.50 | 18.81% | Buy |
INNV | InnovAge | $5.90 | $6.80 | 15.25% | Hold |
SEM | Select Medical | $36.51 | $40.00 | 9.56% | Buy |
PNTG | Pennant Group | $32.38 | $34.67 | 7.07% | Buy |
UHS | Universal Health Services | $208.83 | $208.47 | -0.17% | Hold |
ENSG | Ensign Group | $153.39 | $148.20 | -3.38% | Buy |
THC | Tenet Healthcare | $162.38 | $128.60 | -20.80% | Buy |
CANO Forecast FAQ
Is Cano Health a good buy?
Yes, according to 3 Wall Street analysts, Cano Health (CANO) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 66.67% of CANO's total ratings.
What is CANO's price target?
Cano Health (CANO) average price target is $6.42 with a range of $1.25 to $13, implying a 1505.00% from its last price of $0.4. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Cano Health stock go up soon?
According to Wall Street analysts' prediction for CANO stock, the company can go up by 1505.00% (from the last price of $0.4 to the average price target of $6.42), up by 3150.00% based on the highest stock price target, and up by 212.50% based on the lowest stock price target.
Can Cano Health stock reach $1?
CANO's average twelve months analyst stock price target of $6.42 supports the claim that Cano Health can reach $1 in the near future.
What are Cano Health's analysts' financial forecasts?
CANO's analysts financial forecasts for the fiscal year (Dec 2023) are as follows: average revenue is $3.13B (high $3.17B, low $3.09B), average EBITDA is $70.01M (high $71.07M, low $69.25M), average net income is $-343M (high $-16.946B, low $-28.648B), average SG&A $468.46M (high $475.57M, low $463.36M), and average EPS is $-0.65 (high $-32.104, low $-54.273).
Did the CANO's actual financial results beat the analysts' financial forecasts?
In terms of the last quarterly report (Sep 2023), Cano Health's revenue was $788.07M, beating the average analysts' forecast of $759.84M by 3.72%. The company's EBITDA was $-65.859M, missing the average prediction of $17.02M by -486.91%. Cano Health's net income was $-260M, beating the average estimation of $-121M by 114.56%. The company's SG&A was $80.82M, missing the average forecast of $113.9M by -29.04%. Lastly, the company's EPS was $-91.87, beating the average prediction of $-0.23 by 39843.48%